Marshall, A. (Andrea), Dunn, Janet A., Fletcher, Julie, Higgins, Helen B. and Poole, Christopher (2011) The importance of planning for a seamless transition in an adaptive phase II randomised trial. Trials, Vol.12 (Suppl.1). A7. ISSN 1745-6215

HER2 TOP2A Meta-Anal Study Group (Including:

). (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data. Lancet Oncology, Vol.12 (No.12). pp. 1134-1142. ISSN 1470-2045

Campbell, H. E., Epstein, D., Bloomfield, D., Griffin, S., Manca, A., Yarnold, J., Bliss, J., Johnson, L., Earl, H., Poole, Christopher, Hiller, Louise, Dunn, Janet A., Hopwood, P., Barrett-Lee, P., Ellis, P., Cameron, D., Harris, A. L., Gray, A. M. and Sculpher, Mark J.. (2011) The cost-effectiveness of adjuvant chemotherapy for early breast cancer : a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, Vol.47 (No.17). pp. 2517-2530. ISSN 0959-8049

Rustin, G., Reed, N., Jayson, G. C., Ledermann, J. A., Adams, M., Perren, T., Poole, Christopher, Lind, M., Persic, M., Essapen, S., Gore, M., Calvert, H., Stredder, C., Wagner, A., Giurescu, M. and Kaye, S.. (2011) A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology, Vol.22 (No.11). pp. 2411-2416. ISSN 0923-7534

Forster, Martin D., Dedes, Konstantin J., Sandhu, Shahneen, Frentzas, Sophia, Kristeleit, Rebecca, Ashworth, Alan, Poole, Christopher J., Weigelt, Britta, Kaye, Stan B. and Molife, L. Rhoda. (2011) Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature Reviews Clinical Oncology, Vol.8 (No.5). pp. 302-306. ISSN 1759-4774

Poole, Christopher, Lisyanskaya, A., Rodenhuis, S., Kristensen, G., Lauraine, E. Pujade, Cantarini, M., Emeribe, U., Stuart, M. and Coquard, I. Ray (2010) A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive epithelial ovarian cancer (eoc). In: 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8-12 Oct 2010. Published in: Annals of Oncology, Vol.21 (Suppl. 8). pp. 304-305.

Bartlett, J. M. S., Munro, A., O'Malley, F. P., Earl, H., Poole, Christopher, Cardoso, F., Twelves, C. J., Pritchard, K. I., Rea, D. W. and Di Leo, A. (2010) Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group. In: European Breast Cancer Conference, Barcelona, Spain, March 24, 2010. Published in: European Journal of Cancer Supplements, Vol.8 (No.3). p. 121.

Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D. (David), 1956-, Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M. and Poole, Christopher. (2010) Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3). pp. 266-274. ISSN 1470-2045

Bartlett, J. M. S., Munro, A., Desmedt, C., Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, H., Poole, Christopher, Shepherd, L., Cardoso, F., Caldas, C., Twelves, C. J., Pritchard, K., Rea, D. W. and diLeo, A. (2009) Duplication of chromosome 17 CEP predicts for anthracycline benefit: a meta-analysis of 4 trials. In: 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 09-13, 2009. Published in: Cancer Research, Vol.69 (No.24 Suppl. 3). 716S-716S.

TACT Trial Management Grp, TACT Trialists (Including:

). (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial. Lancet, Vol.373 (No.9676). pp. 1681-1692. ISSN 0140-6736

Bartlett, J. M. S., Munro, A., Dunn, Janet A., Hiller, Louise, Jordan, S., Twelves, C. J., Cameron, D. A., Thomas, J., Campbell, F., Rea, D. W., Provenzano, E., Pharoah, P., Caldas, C., Earl, H. and Poole, Christopher (2009) Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEA Tadjuvant breast cancer trial. In: 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008. Published in: Cancer Research, Vol.69 (No.2 Suppl. S). 74S-74S.

Behalf NEAT Investigators (Including: Earl, H. M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, D. and Poole, Christopher). (2008) NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8). pp. 1226-1231. ISSN 0007-0920

tAnGo Trial Collaborators (Including: Wardley, A. M., Hiller, Louise, Howard, H. C., Dunn, Janet A., Bowman, A., Coleman, R. E., Fernando, I. N., Ritchie, D. M., Earl, H. M. and Poole, Christopher). (2008) tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer : a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, Vol.99 (No.4). pp. 597-603. ISSN 0007-0920

Kaye, Stan B., Poole, Christopher, Bidzinksi, M., Gianni, L., Gorbunova, V., Novikova, E., Strauss, A., McNally, V. A., Rossi, G. and Vergote, Ignace. (2008) A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology, Vol.26 (No.15S). p. 5520. ISSN 0732-183X

Gray, R. G., Rea, D. W., Handley, K., Marshall, A. (Andrea), Pritchard, M. G., Perry, P., Earl, H. M., Poole, Christopher, Salman, A. and Lee, M. (2008) aTTom (adjuvant Tamoxifen--To offer more?) : randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results. In: 2008 ASCO Annual Meeting, Chicago, Illinois, 30 May-3 Jun 2008. Published in: Journal of Clinical Oncology, Vol.26 (No.15S (May 20 Supplement)). p. 513.